Sunitinib treatment of RCC patients led to an increase in serum bFGF levels, irrespective of the treatment outcome, although patients with no response to sunitinib presented higher bFGF levels than the ones with a temporary clinical benefit or a better response [71]. This evidence concerns the gene FGF2 and renal cell carcinoma.